Novel targets for platelet inhibition.
Atherothrombosis often underlies coronary artery disease, stroke, and peripheral arterial disease. Antiplatelet drugs have come to the forefront of prophylactic treatment of atherothrombotic disease. Dual antiplatelet therapy of aspirin plus clopidogrel-the current standard-has benefits, but it also has limitations with regard to pharmacologic properties and adverse effects with often severe bleeding complications. For these reasons, within the last decade or so, the investigation of novel antiplatelet targets has prospered. Target identification can be the result of large-scale genomic or proteomic studies, functional genomics in animal models, the genetic analysis of patients with inherited bleeding disorders, or a combination of these techniques.
Center for Molecular and Vascular Biology, University of Leuven, Herestraat 49, 3000, Leuven, Belgium. Kathleen.Freson@med.kuleuven.be
Kathleen
K
Freson
Chris
C
Van Geet
D000818:Animals; D000242:Cyclic AMP / Q000037:antagonists & inhibitors; D055106:Genome-Wide Association Study; D023281:Genomics; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D040901:Proteomics; D015398:Signal Transduction / Q000187:drug effects
D010975:Platelet Aggregation Inhibitors; D000242:Cyclic AMP